Tackling obesity - not only diabetics benefit from the effects

This content is machine-translated. Please contact us if you need professional translation services.

While glucagon-like peptide (GLP)-1 receptor agonists have been successfully used in the treatment of diabetes for some time, there are now agents that activate not only the GLP-1 receptor but also the glucose-dependent insulinotropic polypeptide (GIP) receptor. Dual GLP-1/GIP agonists are considered promising new drugs for the treatment of obesity and type 2 diabetes.

This content can only be access by registered users.
Log In Register